Prion therapeutics: Lessons from the past
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Shim, Kyu Hwan | - |
dc.contributor.author | Sharma, Niti | - |
dc.contributor.author | An, Seong Soo A | - |
dc.date.accessioned | 2023-01-07T04:40:05Z | - |
dc.date.available | 2023-01-07T04:40:05Z | - |
dc.date.created | 2022-12-23 | - |
dc.date.issued | 2022-12 | - |
dc.identifier.issn | 1933-6896 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/86495 | - |
dc.description.abstract | Prion diseases are a group of incurable zoonotic neurodegenerative diseases (NDDs) in humans and other animals caused by the prion proteins. The abnormal folding and aggregation of the soluble cellular prion proteins (PrPC) into scrapie isoform (PrPSc) in the Central nervous system (CNS) resulted in brain damage and other neurological symptoms. Different therapeutic approaches, including stalling PrPC to PrPSc conversion, increasing PrPSc removal, and PrPC stabilization, for which a spectrum of compounds, ranging from organic compounds to antibodies, have been explored. Additionally, a non-PrP targeted drug strategy using serpin inhibitors has been discussed. Despite numerous scaffolds being screened for anti-prion activity in vitro, only a few were effective in vivo and unfortunately, almost none of them proved effective in the clinical studies, most likely due to toxicity and lack of permeability. Recently, encouraging results from a prion-protein monoclonal antibody, PRN100, were presented in the first human trial on CJD patients, which gives a hope for better future for the discovery of other new molecules to treat prion diseases. In this comprehensive review, we have re-visited the history and discussed various classes of anti-prion agents, their structure, mode of action, and toxicity. Understanding pathogenesis would be vital for developing future treatments for prion diseases. Based on the outcomes of existing therapies, new anti-prion agents could be identified/synthesized/designed with reduced toxicity and increased bioavailability, which could probably be effective in treating prion diseases. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | TAYLOR & FRANCIS INC | - |
dc.relation.isPartOf | Prion | - |
dc.title | Prion therapeutics: Lessons from the past | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000898263300001 | - |
dc.identifier.doi | 10.1080/19336896.2022.2153551 | - |
dc.identifier.bibliographicCitation | Prion, v.16, no.1, pp.265 - 294 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.scopusid | 2-s2.0-85144588482 | - |
dc.citation.endPage | 294 | - |
dc.citation.startPage | 265 | - |
dc.citation.title | Prion | - |
dc.citation.volume | 16 | - |
dc.citation.number | 1 | - |
dc.contributor.affiliatedAuthor | Shim, Kyu Hwan | - |
dc.contributor.affiliatedAuthor | Sharma, Niti | - |
dc.contributor.affiliatedAuthor | An, Seong Soo A | - |
dc.type.docType | Review | - |
dc.subject.keywordAuthor | anti-prion agents | - |
dc.subject.keywordAuthor | CJD | - |
dc.subject.keywordAuthor | mode of action | - |
dc.subject.keywordAuthor | Prions disease | - |
dc.subject.keywordAuthor | therapeutics | - |
dc.subject.keywordAuthor | transmissible spongiform encephalopathies | - |
dc.subject.keywordPlus | TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY | - |
dc.subject.keywordPlus | INTRAVENTRICULAR PENTOSAN POLYSULFATE | - |
dc.subject.keywordPlus | CREUTZFELDT-JAKOB-DISEASE | - |
dc.subject.keywordPlus | III HISTONE DEACETYLASE | - |
dc.subject.keywordPlus | PROTEASE-RESISTANT PRP | - |
dc.subject.keywordPlus | ACCUMULATION IN-VITRO | - |
dc.subject.keywordPlus | NEURONAL CELL-DEATH | - |
dc.subject.keywordPlus | DEXTRAN SULFATE 500 | - |
dc.subject.keywordPlus | CONGO-RED | - |
dc.subject.keywordPlus | ALZHEIMERS-DISEASE | - |
dc.relation.journalResearchArea | Biochemistry & Molecular Biology | - |
dc.relation.journalWebOfScienceCategory | Biochemistry & Molecular Biology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.